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I M M U N O L O G Y
CRISPR-based gene editing enables FOXP3 gene  
repair in IPEX patient cells
M. Goodwin1*, E. Lee1,2*, U. Lakshmanan1, S. Shipp1, L. Froessl1, F. Barzaghi3,  
L. Passerini3, M. Narula1, A. Sheikali1, C. M. Lee4, G. Bao5, C. S. Bauer6, H. K. Miller6,  
M. Garcia-Lloret7, M. J. Butte7, A. Bertaina1, A. Shah1, M. Pavel-Dinu1, A. Hendel1,8,  
M. Porteus1,2, M. G. Roncarolo1,2, R. Bacchetta1†
The prototypical genetic autoimmune disease is immune dysregulation polyendocrinopathy enteropathy X-linked 
(IPEX) syndrome, a severe pediatric disease with limited treatment options.  IPEX syndrome is caused by mutations in 
the forkhead box protein 3 (FOXP3) gene, which plays a critical role in immune regulation.  As a monogenic disease, 
IPEX is an ideal candidate for a therapeutic approach in which autologous hematopoietic stem and progenitor (HSPC) 
cells or T cells are gene edited ex vivo and reinfused.  Here, we describe a CRISPR-based gene correction permitting 
regulated expression of FOXP3 protein.  We demonstrate that gene editing preserves HSPC differentiation potential, 
and that edited regulatory and effector T cells maintain their in vitro phenotype and function.  Additionally, we show 
that this strategy is suitable for IPEX patient cells with diverse mutations.  These results demonstrate the feasibility 
of gene correction, which will be instrumental for the development of therapeutic approaches for other genetic 
autoimmune diseases.
INTRODUCTION
Primary immunodeficiencies comprise a group of genetic immune 
diseases, which typically present with recurrent infections, but may 
instead manifest with predominant autoimmunity (1, 2). Over 
350 monogenic immune diseases have been described to date, and 
this number has been rapidly increasing with technological advances 
in DNA sequencing and expanding accessibility of genetic screen-
ing (1). The prototype of genetic autoimmunity is immune dys-
regulation polyendocrinopathy enteropathy and X-linked (IPEX) 
syndrome, which is a severe X-linked disease with early onset (2, 3). 
The most frequent autoimmune manifestations of IPEX syndrome 
include type 1 diabetes, eczema, and life-threatening enteropathy 
(4). Other common autoimmune manifestations include cytopenia, 
autoimmune hepatitis, and thyroiditis. IPEX syndrome is classified 
as a Tregopathy, a class of diseases that selectively affect the func-
tion of regulatory T cells (Tregs) and, in the case of IPEX syndrome, 
CD4+CD25highFOXP3+ Tregs (5, 6). In patients with IPEX, non-
functional Tregs are produced that are unable to prevent the devel-
opment of autoimmunity or allergy because they lack the ability 
to suppress the function and proliferation of effector T (Teff) cells 
(7). In recent years, the pathophysiology of IPEX syndrome has 
been dissected, but few therapeutic advances have been made, and 
limited treatment options exist (2). Currently, patients with IPEX 
are treated with pharmacological immunosuppression, which has 
only partial efficacy in the acute phase of the disease and cannot 
prevent long-term disease progression (2, 4). Furthermore, ad-
ministration of immunosuppressive drugs carries the risk of severe 
side effects associated with toxicity and susceptibility to infections. 
The only curative treatment available for IPEX is allogeneic he-
matopoietic stem cell transplantation. However, many patients do 
not find a suitable donor or suffer from transplant-related compli-
cations (4).
IPEX syndrome is caused by mutations in the forkhead box 
protein 3 (FOXP3) gene, and over 70 unique mutations throughout 
the FOXP3 locus have been identified (4, 8). FOXP3 is a master tran-
scription factor required for the function of Tregs, which up-regulates 
Treg-associated markers, such as CD25 and CTLA-4, and represses 
proinflammatory cytokine production (9). While Tregs rely on con-
stitutive FOXP3 expression, Teff cells transiently express FOXP3 
following T cell receptor (TCR) activation (7). This cell type–specific 
regulation is a result of a complex network of promoter and enhancer 
elements (9, 10). The high and persistent FOXP3 expression in Tregs 
is due to epigenetic marks established during T cell development, 
including the Treg-specific demethylated region (TSDR) (10). It has 
previously been shown that Teff cells require transient FOXP3 ex-
pression for intrinsic regulation of proliferation, cytokine production, 
and TCR signaling (11, 12). According to the current understanding 
of IPEX, impairment of both Teff and Treg function underlies IPEX 
syndrome pathology (2, 9). In human Teff cells and Tregs, FOXP3 
pre-mRNA is alternatively spliced, and the two predominant spliced 
isoforms are the full-length (FOXP3FL) isoform and a shorter 
version that lacks exon 2 (FOXP3dE2) (13, 14). The FOXP3FL and 
FOXP3dE2 isoforms each represent roughly half of the FOXP3 ex-
pressed; however, the proportion is skewed in different cell activa-
tion states and in a number of inflammatory diseases (14). Causative 
IPEX mutations in exon 2 have been described, with a subset of pa-
tients presenting with milder clinical phenotypes (15, 16). Because 
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these mutations spare the FOXP3dE2 isoform, it has been suggested 
that FOXP3dE2 can partially compensate for FOXP3FL loss but that 
FOXP3FL is required for complete Treg and Teff cell function and pre-
vention of IPEX syndrome (16).
Because IPEX syndrome is a monogenic immune disease caused 
by mutations in FOXP3, gene therapy could be a useful approach to 
treat the disease. We previously developed a FOXP3 gene delivery 
protocol for ex vivo generation of genetically engineered Tregs that 
uses lentiviral vector (LV)–mediated delivery of copy of the com-
plementary DNA (cDNA) of the full-length isoform of FOXP3 (17). 
Because this vector expresses FOXP3 under a constitutive pro-
moter, EF1, it is able to convert IPEX patient conventional CD4+ 
T cells into potent Treg-like suppressor cells. We are currently opti-
mizing the LV-FOXP3 system for use as a T cell–based therapy 
for patients with IPEX. However, this approach does not address 
other cell types, such as Teff cells, that also contribute to the IPEX 
pathology. An additional limitation of this approach is that it 
cannot be used on long-term repopulating hematopoietic stem and 
progenitor cells (HSPCs) because of the adverse effects of FOXP3 
overexpression on stem cell proliferation and differentiation (18). 
For the development of a successful FOXP3 gene therapy using 
HSPCs, it is necessary to achieve constitutive expression of FOXP3 
in the Treg compartment to restore suppressive function without 
having FOXP3 overexpression perturb the proliferation and func-
tion of HSPCs or Teff cells. To maintain this cell type–specific ex-
pression, an ideal approach would precisely deliver FOXP3 to its 
endogenous gene locus and allow regulation of FOXP3 in its own 
genomic context.
To deliver the FOXP3 cDNA in a site-specific manner while 
preserving endogenous regulation, we propose gene editing with the 
clustered regularly interspaced short palindromic repeat (CRISPR)–
CRISPR-associated protein 9 (Cas9) system. In general, this one-
size-fits-all cDNA insertion approach is designed to benefit all or 
the majority of patients, given that the causative mutations are 
located downstream of the insertion site (19, 20). We hypothe-
sized that this site-specific approach would permit gene delivery 
to patient-derived HSPCs for an autologous transplant. This gene 
correction approach could provide a more complete and long-term 
treatment for IPEX syndrome and circumvent the need for matched 
hematopoietic stem cell donors. Here, we combine the CRISPR 
system with a DNA repair homology donor to insert the FOXP3 
cDNA into the endogenous locus via homology-directed repair 
(HDR). We report that this gene editing platform can accurately 
and specifically target FOXP3 in HSPCs and that edited HSPCs 
maintain normal differentiation potential in vitro and in vivo in 
immunodeficient mice. We demonstrate that both Tregs and Teff 
cells retain their key biologic properties when the cDNA is inserted 
into the endogenous locus, including normal proliferation of Teff 
cells. We show that the FOXP3 gene can be corrected in cells from 
patients with IPEX with diverse mutations, which demonstrates 
the feasibility of a CRISPR-based FOXP3 gene correction approach 
for IPEX syndrome.
RESULTS
Efficient and precise editing of FOXP3 locus in human HSPCs 
and T cells using CRIS
To achieve gene editing at the FOXP3 locus, we designed a CRISPR 
system targeting the FOXP3 gene downstream of the translation start 
codon in exon 1 (E1) and a corresponding HDR donor containing 
FOXP3 cDNA (Fig. 1A). The donor construct was designed to insert 
a codon-diverged FOXP3 cDNA and restore wild-type (WT) FOXP3 
protein expression in patient cells with diverse and scattered FOXP3 
mutations. The gene replacement donor template was also designed 
to knock-in a marker gene, the truncated nerve growth factor receptor 
(tNGFR), which is used clinically as a surface marker for selection 
and tracking of genetically engineered cells. We placed tNGFR under 
the control of a constitutive promoter such that it would be expressed 
independently of FOXP3. Polyadenylation (pA) signals were included 
in the construct to ensure termination and inactivation of the down-
stream endogenous gene elements. In addition to the full-length 
FOXP3 cDNA construct (FOXP3FL), we also developed two similar 
experimental constructs including a FOXP3 cDNA of a naturally occur-
ring alternatively spliced isoform of FOXP3 lacking exon 2 (FOXP3dE2) 
and a FOXP3 knockout (FOXP3KO) construct that disrupts the 
FOXP3 gene by inserting only the tNGFR maker gene flanked by 
pA signals (fig. S1A).
We screened FOXP3 CRISPR single-guide RNAs (sgRNAs) for 
on-target cutting activity in immortalized K562 cells (Fig. 1B, fig. 
S1B, and table S1). The sgRNAs 1 and 2 triggered the highest on-target 
activity (26 ± 7% and 20 ± 5%, respectively, mean ± SD, n = 4) 
(Fig. 1B), as indicated by the frequency of insertion deletion (indel) 
mutations detected by TIDE analysis (21). Of the sgRNAs screened, 
sgRNA 2 was selected because of a combination of its on-target 
activity, safe predicted off-target profile, location in the coding se-
quence of the gene, and proximity to the start codon. Cutting effi-
ciency of sgRNA 2 was 28 ± 6% in human CD34+ HSPCs and 
88 ± 7% in CD4+ T cells (mean ± SD, n = 4), thus validating that the 
CRISPR system efficiently targets FOXP3 in the primary cells of 
interest (Fig. 1, C and D).
Using FOXP3 sgRNA 2, we edited the allele via the HDR-mediated 
pathway by transducing HSPCs with a FOXP3 DNA repair donor 
delivered as a recombinant adeno-associated virus of serotype 6 
(rAAV6) (22, 23). Similarly, we gene edited CD4+ T cells to enable 
functional testing on T cells. We detected successful HDR as evi-
denced by an in-out polymerase chain reaction (PCR) amplification 
of genomic DNA (Fig. 2A and fig. S2A). Precise insertion and the 
FOXP3 cDNA sequence were confirmed by sequencing analysis 
(table S1). Rates of HDR-mediated editing detected by tNGFR ex-
pression were 14 ± 7% in primary CD4+CD25high Tregs (n = 14), 
17 ± 5% in the immortalized MT-2 Treg-like cell line (n = 7) (24), 
24 ± 10% in CD4+CD25−/low Teff cells (n = 21), and 29 ± 8% in HSPCs 
(n = 27) (Fig. 2B). Testing of the alternative constructs, FOXP3dE2 
and FOXP3KO, in HSPCs revealed average HDR rates of 26 ± 9% and 
23 ± 5%, respectively (fig. S2B). To confirm that tNGFR expression 
was an accurate measure of editing rates, we performed editing on 
HSPCs from three cell donors and tested editing in each donor in 
parallel by both tNGFR expression and a quantitative in-out PCR 
using the Digital Droplet PCR (ddPCR) system (19). We found con-
cordance between the two methods of editing detection, 25 ± 2% 
editing for tNGFR flow cytometry and 29 ± 5% for ddPCR (n = 3), 
confirming the accuracy of detection (fig. S2C). Mock-treated cells 
were nucleofected and transduced with rAAV-donor templates in 
the absence of CRISPR and showed low levels of background episomal 
tNGFR expression (Fig. 2C and fig. S2D). Enrichment of edited cells 
using the tNGFR maker resulted in a population consistently above 
90% purity (Fig. 2C), confirming that tNGFR could be used to isolate 
a pure population of edited cells.
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Specific FOXP3 gene editing in HSPC using CRISPR
We investigated off-target activity using three complementary meth-
ods: bioinformatic prediction, a double-strand break (DSB) capture 
assay, and next-generation sequencing (NGS). Initially, 58 potential 
off-target sites were predicted by bioinformatic in silico prediction 
using the CRISPR Search with Mismatches, Insertions and/or Dele-
tions (COSMID) tool (25), of which 96% were in noncoding regions 
of the genome (fig. S2E and tables S2 and S3, A to E). Ten off-target 
sites were identified using DSB capture by genome-wide, unbiased 
identification of DSBs enabled by sequencing (GUIDE)–seq GUIDE- 
seq (26) in the U2OS cell line, of which seven were also predicted by 
in silico analysis (Fig. 2D and fig. S2F). The 61 sites predicted by the 
combination of COSMID and GUIDE-seq were then evaluated in 
FOXP3 edited HSPCs by NGS. Four sites were validated by NGS, 
three of which were identified by all three methods. The four sites 
identified as off-targets were ranked as 1, 3, 4, and 14 by the COS-
MID algorithm. When excluding a mismatch at the 5′ distal nucle-
otide, none of the validated sites had more than three mismatches. 
As compared with the NGS-identified indel rates in the FOXP3 gene 
of 42 and 44% in edited cord blood– and bone marrow–derived 
HSPCs, respectively, all off-target sites had less than 2% targeting 
(Fig. 2E). None of the validated sites were in coding regions of genes, 
and on the basis of gene annotation, none of the sites would have 
a clear impact on hematopoiesis or cell cycle regulation in hema-
topoietic cells. The results from this off-target analysis suggest that 
the FOXP3 CRISPR system is a relatively specific platform for gene 
editing in hematopoietic cells.
Persistent FOXP3 protein expression and preserved Tregs 
phenotype and function in FOXP3 edited Tregs
We next evaluated our FOXP3 cDNA insertion strategy in Tregs, the 
major cell type that expresses FOXP3 and is implicated in IPEX syn-
drome. We used the immortalized MT-2 Treg cell line and primary 
peripheral blood–derived Tregs separated by CD25 enrichment beads. 
The purity of the primary Tregs was confirmed by flow cytometry 
and epigenetic TSDR demethylation (fig. S3, A and B). We initially 
tested FOXP3 expression in MT-2 cells and observed that FOXP3FL 
edited cells expressed FOXP3 protein, but at a lower level compared 
with unmodified MT-2 cells (Fig. 3A and fig. S4A). In contrast, edit-
ing with the FOXP3KO construct led to complete loss of FOXP3 pro-
tein expression as predicted (fig. S4B). Insertion of the second 
isoform of FOXP3 (FOXP3dE2) led to approximately 50% FOXP3 
expression relative to WT cells (fig. S5A), revealing that delivery of 
either isoform cDNA individually can support a similar level of 
FOXP3 expression in Tregs. To improve FOXP3 protein expression, we 
designed two additional constructs: a codon-optimized FOXP3 cDNA 
FOXP3 gene
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construct (FOXP3FLco) and the codon-optimized FOXP3 construct 
followed by a woodchuck hepatitis virus posttranscriptional regu-
latory element (FOXP3co + WPRE or FOXP3FLcoW), added to in-
crease mRNA stability and protein translation (Fig.  3B) (20). 
The FOXP3co construct yielded similar FOXP3 protein levels to 
the FOXP3FL construct, whereas the FOXP3FLcoW construct re-
sulted in moderately increased FOXP3 protein expression levels 
(Fig. 3C).
We next evaluated FOXP3 expression in human peripheral 
blood–derived CD4+CD25high Tregs. The pattern of FOXP3 expres-
sion from the different donor constructs in MT-2 cells was reflected 
in peripheral blood–derived Tregs. Tregs edited with the FOXP3FL 
cDNA expressed a lower level of FOXP3 protein, and a modest in-
crease in FOXP3 protein expression from the FOXP3FLcoW construct 
was observed (Fig. 3D). While the various cDNA donors were 
not able to fully reach WT levels of FOXP3 protein expression in 
the MT-2 Treg cell line or primary Tregs, we hypothesized that this 
level of FOXP3 protein expression might still be sufficient to restore 
Treg function.
Immunophenotypic analysis for Treg cell markers, including 
TIGIT, HELIOS, PD1, CTLA-4, and CD25, revealed that all markers 
were expressed in FOXP3 edited Tregs (Fig. 3E). The average intensity 
of HELIOS was decreased after editing, but there was no statistically 
significant difference in HELIOS expression between edited and mock- 
treated samples. Overall, the expression levels of all Treg makers were 
similar in WT and edited Tregs with no statistically significant differences 
observed (Fig. 3E). These results suggest that the CRISPR edited Tregs 
maintain the expression of key proteins characteristic of WT Tregs.
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We next tested the function of gene edited Tregs and their hall-
mark ability to suppress the proliferation of activated Teff cells in a 
coculture suppression assay. WT Tregs from healthy donors displayed 
suppression capacity at an average of 69 ± 17% (mean ± SD) (Fig. 3F). 
In contrast, IPEX Tregs and FOXP3 knockout Tregs displayed dimin-
ished suppression at rates of 7 ± 3% and 8 ± 7%, respectively 
(Fig. 3F). Tregs that were edited with the various FOXP3 cDNA knock-in 
constructs all displayed suppressive function, although not fully 
reaching the level of WT Tregs [FOXP3FL 45 ± 12%, n = 7, *P < 0.05 
versus WT; FOXP3co 43 ± 16%, n = 2, P = ns (not significant); 
FOXP3FLcoW 50 ± 5%, n = 4, P = ns] (Fig. 3F). In addition, we tested 
the suppressive function of FOXP3dE2 Tregs and found them to per-
form comparably to FOXP3FL and FOXP3FLcoW edited Tregs (fig. S5, 
B and C). As a negative control, FOXP3FLcoW edited Teff cells that 
were cultured and edited in parallel were tested and found to lack 
suppressive function (fig. S5, C and D). Given the ability to suppress 
Teff proliferation and the relatively higher FOXP3 expression, we 
selected the FOXP3FLcoW construct for subsequent functional testing. 
Overall, FOXP3 cDNA knock-in Tregs displayed suppressive func-
tion that overlapped with lower normal range of suppressive func-
tion observed in WT Tregs from different donors, suggesting that 
editing might be sufficient to restore suppressive capacity to non-
functional Tregs.
Physiologically regulated FOXP3 expression and preserved 
function in FOXP3 edited Teff cells
Because Teff cells transiently express FOXP3 upon TCR activation, 
we monitored FOXP3 protein expression in FOXP3 edited Teff cells 
by flow cytometry over a 2-week time course after activation. In non-
activated cells, a low level of background FOXP3 expression was ob-
served, likely due to the pre-editing activation and culturing (Fig. 4A). 
Upon TCR-mediated reactivation, FOXP3 expression in both edited 
cells and controls was induced and nearly doubled by day 3 before 
gradually returning to baseline (Fig. 4A). Overall, the regulation of 
FOXP3 expression in Teff cells closely mirrored that in WT controls 
without statistically significant differences, confirming that endog-
enous regulation of expression was preserved.
In addition to FOXP3 expression, we evaluated the cytokine pro-
duction profile and proliferation potential of gene edited Teff cells 
and controls to demonstrate that the intrinsic regulatory effect of 
FOXP3 was maintained. High levels of interferon- (IFN-) and low 
levels of interleukin-2 (IL-2) were produced in both WT and FOXP3 
edited Teff cells (Fig. 4B). IL-17 production was higher in FOXP3 
edited Teff cells, but not statistically different as compared with the 
WT control (Fig. 4B). In addition, all edited and nonedited Teff cells 
displayed similar kinetics of activation-induced proliferation over 
time that was dependent on the strength of activation (Fig. 4C and 
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fig. S6). Together, these results indicate that FOXP3 edited Teff cells 
maintain physiological regulation of FOXP3 expression, cytokine 
production, and proliferation.
Restored functional FOXP3 expression to IPEX patient Tregs 
and Teff cells after CRISPR-based FOXP3 editing
We obtained cells from six patients with IPEX, including two sets of 
brothers with identical pathologic mutations (mutation locations are 
depicted in Fig. 5A; see table S4 for patient information). Mutations 
ranged from point mutations to complete abrogation of gene ex-
pression. Gene editing of IPEX T cells using the FOXP3 CRISPR 
system resulted in precise HDR-mediated editing as revealed by 
in-out PCR of the edited locus (Fig. 5B). In addition, HDR rates 
determined by tNGFR expression revealed that IPEX cells could all 
be targeted with comparable efficiency as healthy donor cells [editing 
rates for IPEX patients (pt.) 24 and 64 are shown and were repro-
duced in pt. 37, 65, 77, and 78; Fig. 5C].
Gene editing restored expression of FOXP3 in gene edited IPEX 
T cells harboring different mutations. We edited IPEX pt. 24 cells, 
which harbor a c.210+1G>C mutation that disrupts the exon-intron 
border of the first coding exon and leads to aberrant E1 skipping 
(27). FOXP3 mRNA isoforms in this patient are shorter due to the 
missing E1 as shown by reverse transcription (RT)–PCR (Fig. 5D). 
Gene editing of FOXP3 in IPEX pt. 24 cells with the full-length FOXP3 
cDNA construct restored expression of the full-length FOXP3 mRNA 
isoform (Fig. 5D). We also analyzed mRNA expression after gene 
editing of T cells from IPEX pt. 37, carrying a c.1150G>A mutation 
that leads to an alanine-to-threonine amino acid change. RT-PCR 
and Sanger sequencing revealed that the edited pt. 37 cells expressed 
FOXP3 mRNA from the inserted FOXP3 codon-diverged cDNA 
construct, as confirmed by a restoration of a codon encoding for the 
correct alanine residue (Fig. 5E). In addition, the entire mRNA was 
sequenced to ensure that precise HDR-mediated FOXP3 cDNA inser-
tion led to the predicted full-length mRNA encoding WT FOXP3 
protein. Together, these results provide evidence that the FOXP3 
CRISPR system can be used to restore expression of FOXP3 in T cells 
from patients with IPEX with diverse mutations.
We next evaluated proliferative responses of FOXP3 gene–edited 
Teff cells from IPEX pt. 77 and 78. Compared with WT healthy donor 
Teff cells, the Teff cells from both pt. 77 and 78 proliferated at an 
accelerated rate (Fig. 5F), consistent with previous findings that FOXP3 
loss leads to hyperproliferation (12). FOXP3 gene editing was able 
to normalize proliferation rates closer to the level of healthy donor 
Teff cells, showing that restoration of FOXP3 expression reestablished 
regulation of proliferation in IPEX Teff cells (Fig. 5F). To test for 
restoration of Treg-suppressive activity in IPEX cells, we gene edited 
Tregs of IPEX pt. 64. The WT Tregs from healthy donor displayed 
suppressive function (40%) in coculture conditions with Teff responder 
cells, whereas IPEX pt. 64 Tregs showed diminished suppressive function 
(4%) (Fig. 5G). Gene editing of IPEX pt. 64 Tregs with the FOXP3FLcoW 
construct was able to increase suppressive function (32%) near the 
levels typical of healthy donor–edited cells (Fig. 5G), and these 
results were confirmed on two independent blood draws. Together, 
the results from functional analyses of edited IPEX Treg and Teff cells 
show that FOXP3 correction using the CRISPR system restores physio-
logical regulation of WT FOXP3 expression and has the potential to 
provide a functional benefit to IPEX patient cells.
We then evaluated the differentiation potential of FOXP3 edited 
HSPCs using in vitro and in vivo approaches to confirm safety and 
feasibility. We performed in vitro colony-forming unit (CFU) assays 
to test the short-term differentiation of FOXP3 edited HSPCs into 
myeloid and erythroid lineages. As compared with WT controls, the 
FOXP3 edited HSPCs differentiated into hematopoietic progenitor 
colonies at similar rates with no statistically significant differences 
(Fig. 6A). We then tested the in vivo engraftment and multilineage 
reconstitution of edited HSPCs in a humanized mouse (hu-mouse) 
model. FOXP3FLcoW edited and control HSPCs (WT unmodified and 
WT mock) were injected into the liver of 3- to 4-day-old neonatal 
immunodeficient mice, and engraftment was monitored over a 
14-week time course (Fig. 6B). The NSG-SGM3 strain of mice was 
selected for engraftment studies because of their expression of several 
human cytokines and their reported higher proportion of FOXP3+ 
Tregs relative to standard NSG mice (28). Before injection, edited 
HSPCs were phenotyped by flow cytometry for purity (%CD34+) 
and markers of hematopoietic progenitor subsets (fig. S7A). Gene 
edited and control HSPCs from three cord blood donors were 
injected, without prior enrichment for tNGFR, into three correspond-
ing litters of mice. A total of 27 mice were injected, including 10 
FOXP3FLcoW edited, 9 WT unmodified, and 8 WT mock conditions. 
The overall survival of the mice over the course of the study was 
comparable among conditions (fig. S7B). Human cell engraftment, 
determined by flow cytometric analysis of hCD45+ expression, steadily 
increased over time in the peripheral blood of the mice and was 
found to be comparable among conditions with no statistically sig-
nificant differences (Fig. 6C).
Multilineage human engraftment was observed in the peripheral 
blood, bone marrow, and spleen in all experimental mice (Fig. 6, 
D and E). The tNGFR+ edited cells persisted in vivo (fig. S7, C to E), 
although three mice were excluded for having less than 5% tNGFR+ 
cells. Analysis of editing rates comparing the proportion of alleles 
edited by HDR (cDNA insertion) and nonhomologous end joining 
(NHEJ) (indels) relative to WT alleles in the bone marrow of the 
mice revealed similar proportions to that of the edited HSPCs be-
fore injection with no apparent abnormal expansion of edited cells 
(fig. S7E). The hematopoietic lineages were analyzed by flow cytom-
etry, and among the edited conditions, the cells were subgated into 
tNGFR+ and tNGFR− fractions for comparison (Fig. 6, D and E). 
We observed the presence of CD34+ HSPCs, CD56+ natural killer 
cells, CD13+ myeloid cells, CD19+ B cells, and CD3+ T cells in the 
bone marrow of FOXP3FLcoW edited (tNGFR+ and tNFGR− fraction) 
and control mice (Fig. 6, D and E). T cell subsets were further eval-
uated in the spleen, with CD3+, CD4+ single-positive, CD8+ single- 
positive, CD4+CD8+ double-positive, CD4+CD25+FOXP3+ Tregs, 
memory CD4+CD45RA−, and naïve CD4+CD45RA+ T cells all present 
in both FOXP3FLcoW edited (tNGFR+ and tNFGR− fraction) and 
control mice (Fig. 6, D and E). Some differences in the frequencies 
of cell subsets were observed between conditions, such as higher 
proportion of CD3+ cells and a lower proportion of CD25+FOXP3+ 
cells in the tNGFR+ fraction. However, no overt changes to immune 
reconstitution were observed, and each hematopoietic cell lineage was 
represented among the different experimental conditions (Fig. 6E).
To test the function of Tregs and Teff cells derived from in vivo 
differentiation of edited HSPCs, we sorted CD3+CD4+ T cells from 
hu-mouse spleens and separated them into CD25high (Treg) and 
CD25low (Teff) fractions. The Treg and Teff fractions from the edited 
conditions were further sorted into tNGFR+ and tNGFR− fractions. 
The purity of FOXP3+ Tregs within the CD25high-sorted fraction was 
tested by epigenetic TSDR demethylation analysis and found to be 
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above 78% for the WT unmodified, mock, and FOXP3FLcoW edited 
tNGFR− and undefined for tNGFR+ fraction due to low cell count. 
Teff cells derived from the hu-mouse were found to proliferate at 
comparable rates to control human peripheral blood–derived Teff 
cells (fig. S7F). Among hu-mouse–derived Teff cells, all conditions 
proliferated at similar rates in a dose-dependent manner relative to 
the strength of activation (fig. S7F). In addition, the CD25high-sorted 
cells were found to be suppressive upon coculture with responder 
Teff cells, and the FOXP3FLcoW edited Tregs displayed comparable sup-
pressive capacity to WT controls (fig. S7G). Overall, these results 
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Fig. 6. FOXP3 edited HSPCs undergo multilineage hematopoietic differentiation and engraftment in vitro and in vivo. (A) Differentiation potential of edited HSPCs 
tested by the in vitro CFU assay. Four resulting hematopoietic progenitor colony types: CFU-E (mature erythroid progenitors), CFU-GEMM (granulocyte, erythrocyte, 
macrophage, and megakaryocyte), BFU-E (primitive erythroid progenitors), and CFU-GM (granulocyte and macrophage progenitors). Representative images of colonies 
from the CFU assay, showing similar morphology (×10 magnification). (B) Experimental timeline of hu-mouse study using NSG-SGM3 mice. (C) Human engraftment 
kinetics in the peripheral blood of hu-mice at corresponding weeks after injection. Engraftment was measured by flow cytometry for hCD45 marker on human cells, and 
frequency was quantified relative to the total of human (hCD45+) and mouse (mCD45+) cells (mean ± SD). (D) Representative flow cytometry plots of engrafted human 
hematopoietic subsets in the bone marrow (left) and spleen (right) of hu-mice at 14 weeks after injection. Populations gated out of human cells (hCD45+). FOXP3 edited 
samples were divided into tNGFR+ and tNGFR− gates for comparability. (E) Quantification of human hematopoietic lineages by flow cytometry with each symbol represent-
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demonstrate that FOXP3 edited HSPCs can engraft in vivo and 
undergo multilineage differentiation, including the production of 
functional Tregs and Teff cells.
DISCUSSION
Monogenic immune and blood disorders are prime candidates for 
gene therapy approaches that target autologous HSPCs. Tradition-
ally, viral vectors, such as LVs, that integrate gene cDNAs semiran-
domly in the genome have been used for gene therapy. While LVs 
have proven to facilitate efficient gene delivery and are now being 
widely tested in clinical trials, they are limited in their ability to pre-
serve locus-specific endogenous regulation of gene expression. For 
this reason, site-specific gene editing has been emerging as a thera-
peutic approach for the delivery of genes that are regulated by a com-
plex network of noncoding elements. Here, we developed a gene 
editing approach for IPEX syndrome, which is a prototypical genetic 
autoimmune disease with unmet medical need. We harnessed site- 
specific gene editing by the CRISPR system to insert a FOXP3 cDNA 
into the endogenous gene locus, preserving spatiotemporal regula-
tion by endogenous regulatory elements.
Using the CRISPR methodology, we efficiently and specifically 
edited FOXP3 in HSPCs and in the two main cell types that express 
FOXP3, Tregs and Teff cells. FOXP3 edited HSPCs did not express 
FOXP3 protein, whereas edited Teff cells transiently expressed FOXP3 
after activation, and edited Tregs persistently expressed FOXP3. This 
cell type–specific expression is consistent with endogenous expression 
patterns. Edited HSPCs maintained their differentiation potential 
and displayed a safe off-target profile. Transient FOXP3 expression 
in Teff cells from healthy donors and patients with IPEX allowed for 
maintenance of normal proliferative potential and cytokine produc-
tion capacity. Persistent expression of FOXP3 in Tregs preserved their 
phenotype and ability to suppress T cell function. The level of FOXP3 
expression in edited Teff cells closely mirrored that of WT cells, 
while edited Tregs displayed partial FOXP3 protein expression. This 
cell type–distinct result could be attributed to the fact that Tregs 
physiologically express a much higher level of FOXP3 than activated 
Teff cells. Although the level of FOXP3 expression in edited Tregs led 
to average suppressive function less than that of WT Tregs from normal 
donors, the suppressive rates of edited cells were still within the lower 
range of nonedited normal donor function. The range in suppres-
sive function among healthy donor Tregs highlights the variability of 
in vitro regulatory function among individuals. Restoration of a sim-
ilar level of FOXP3 expression in IPEX patient Tregs was sufficient to 
reestablish suppressive activity in coculture with Teff cell responders.
By using the CRISPR system, we avoided the delivery of FOXP3 
under a constitutive promoter and subsequent FOXP3 overex-
pression, as in our previously developed LV-EF1-FOXP3 vector 
platform (17). The CRISPR gene editing approach prevents the 
detrimental effects on HSPC proliferation and differentiation caused 
by FOXP3 constitutive overexpression (18). LV-mediated gene de-
livery of FOXP3 with its promoter and enhancer elements has been 
recently reported in mouse models (29). While on the basis of a 
strong rationale, the capacity to restore spatiotemporally regulated 
expression of FOXP3 in human IPEX cells using this vector remains 
to be determined. In general, limitations of LV-mediated delivery 
include the effect of vector copy number on transgene expression 
and the potential for position effect variegation. For example, the 
therapeutic gene could be silenced if positioned into a nonexpressed 
locus or overexpressed if integrated into a site proximal to a strong 
promoter or enhancer. In addition, the semirandom insertion of the 
transgene promoter and enhancer elements into the genome may 
raise concerns of inadvertently activating proto-oncogenes or genes 
that would be detrimental to hematopoiesis. These concerns under-
score the benefits of site-specific gene editing as a more precise method 
for therapeutic gene delivery.
In this study, the CRISPR system enabled efficient HDR-mediated 
editing of FOXP3 in HSPCs, the cell type used for autologous HSPC 
transplantation and long-term reconstitution of the immune system. 
In HSPCs, the overall targeted integration frequency was 29 ± 8% 
when using tNGFR marker to identify targeted cells. In prior studies, 
we observed that targeting frequency increased to 50% or greater 
when the HDR donor was shortened by removal of the tNGFR marker 
gene (19). While the tNGFR marker facilitates enrichment of edited 
cells for functional testing, it may not always be necessary in clinical 
settings. The marker gene could potentially be removed to improve 
editing rates if it becomes apparent that selection and tracking of 
tNGFR-expressing cells are not essential.
While we envision HSPCs being used for autologous transplant, 
the CRISPR system could be applied to adoptive cell therapy using 
differentiated T cells or T cell precursor cells. In addition, the effi-
cient CRISPR-based editing of T cells facilitated functional testing 
of edited Tregs and Teff cells. The T cell functional assays performed 
in this study used the codon-optimized divergent FOXP3 cDNA se-
quence followed by a WPRE, which was expected to provide optimal 
protein expression. To further improve FOXP3 expression and op-
timize the construct, several avenues may be explored. For example, 
different codon-diverged sequences could be evaluated in Tregs, and 
modifications to the CG content of the cDNA could be examined. It 
is also possible that expression from the endogenous FOXP3 gene 
and translation of FOXP3 protein are normally enhanced by endog-
enous intron-exon splice sites and 3′ untranslated region (3′UTR) 
elements. We did not include endogenous FOXP3 introns or 3′UTR 
elements in the cDNA knock-in constructs because of the potential 
for causing premature crossover events during homologous recom-
bination. Thus, additional future modifications to the construct 
aimed at improving expression could include incorporation of short 
exogenous intronic sequences or 3′UTRs from genes highly expressed 
in Tregs.
On the basis of the knowledge that two major spliced isoforms of 
FOXP3 are expressed in human T cells, FOXP3FL and FOXP3dE2 
(13, 14), we speculate that both isoforms could be required to reach 
WT levels of FOXP3 expression in Tregs. We observed that CRISPR- 
based knock-in of either of the two isoforms leads to partial FOXP3 
expression and Treg cell–suppressive function. It has been previously 
shown that overexpression of either isoform is sufficient to confer 
Treg function to conventional CD4+ T cells (13, 30, 31). However, 
these results could have been confounded by the artificially high level 
of forced FOXP3 overexpression and the background genomic ex-
pression of both isoforms. By comparison, CRISPR-mediated knock-
in uses endogenous FOXP3 promoters and enhancers and allows 
each isoform to be expressed individually under physiological con-
ditions. Although expression of each isoform was only ~50 to 60% 
of WT levels, each isoform alone at that level was able to support 
suppressor function within the lower range of healthy donor cells. 
Nonetheless, the ability to deliver individual isoforms into the en-
dogenous locus allows the FOXP3 CRISPR system to be used as a 
tool to investigate the FOXP3FL and FOXP3dE2 isoforms individually. 
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For therapeutic purposes, it may be necessary to use a gene delivery 
platform that preserves expression of both major FOXP3 isoforms. In 
support of this hypothesis, we have previously shown that LV-mediated 
codelivery of both FOXP3FL and FOXP3dE2 cDNAs and subsequent 
simultaneous overexpression of both isoforms in CD4+ T cells were 
able to increase FOXP3 protein expression and confer more potent 
Treg properties than either of the isoforms individually (13). There-
fore, it is possible that the two isoforms work in concert to regulate 
a network of Treg-related genes that drive Treg cell function, and the 
CRISPR system could be used to delineate the distinct and comple-
mentary roles of the FOXP3 isoforms.
The FOXP3 CRISPR system was similarly used as a tool to study 
the effects of complete FOXP3KO. We observed that FOXP3 loss in 
Tregs ablated suppressive function. The tNGFR marker was used to 
isolate a pure population of FOXP3KO cells for functional analysis. 
The ability to purify FOXP3-null cells makes this approach superior to 
an incomplete knockdown or heterogeneous indel-mediated knockout 
of FOXP3 as previously used to investigate the effects of FOXP3 loss 
(11). Thus, the FOXP3 CRISPR system allows for the creation of 
IPEX-like cell models in more readily available healthy donor cells. 
Similarly, the CRISPR system could be used to knock-in FOXP3 
cDNAs harboring patient-specific mutations, which would provide 
insight into the molecular mechanisms underlying the heterogene-
ity of clinical presentation in IPEX syndrome.
While FOXP3 loss in both FOXP3KO and IPEX Tregs abrogated 
suppressive function, FOXP3 cDNA knock-in Tregs displayed in vitro 
function and maintained characteristic Treg phenotypic markers. 
Whether restoring IPEX Tregs to the lower range of normal function 
could be sufficient to provide a stable therapeutic benefit in patients 
with IPEX remains to be addressed. For example, in the context of 
certain disease settings such as hemophilia, it has been shown that 
as little as 5 to 10% gene function can provide therapeutic benefit 
(32–35). Moreover, transplanted patients with IPEX with low over-
all chimerism of donor cells can still undergo tremendous disease 
regression, especially due to the fact that the Treg compartment shows 
a selective advantage toward donor cells (36–38). Similarly, carrier 
mothers display a selective advantage in the Treg compartment such 
that the mutated FOXP3 allele is predominantly located in the inac-
tivated X chromosome, while the WT allele of FOXP3 is expressed 
from the active X chromosome in the Treg compartment (38). These 
observations highlight the selective advantage of cells harboring a 
WT copy of FOXP3 and demonstrate that a small subset of WT Tregs 
can exert a strong protective effect against autoimmunity. We 
observed that FOXP3 CRISPR gene editing of IPEX cells led to 
several improvements, including restoration of WT FOXP3 expres-
sion, increased Treg-suppressive function, and normalization of Teff 
cell proliferation rates.
We evaluated the differentiation potential of FOXP3 edited 
HSPCs using a combination of in vitro and in vivo testing. The dif-
ferentiation of edited HSPCs into myeloid and erythroid lineages 
was confirmed in vitro. The in vivo studies demonstrated engraft-
ment and multilineage hematopoietic reconstitution and allowed us 
to observe lymphocyte lineages in more depth. The gene edited cells 
(tNGFR+ population) persisted in vivo, although in some mice, the 
percentage of tNGFR+ cells was lower than that in the edited HSPC 
population before injection. This decrease could be due to several 
factors, including the previously observed preferential editing of 
short-term progenitor cells over long-term HSCs and the decrease 
in cell viability after gene editing (22, 39). However, the lack of 
expansion of edited cells alleviates any general concerns of clonal 
expansion of genetically modified cells. This notion is further 
underscored by the comparable survival rates of hu-mice engrafted 
with edited and nonedited HSPCs over the course of the study. 
While there were some differences in cell population frequencies 
among conditions, there were no major changes or skewing in 
immune reconstitution. A decrease in the proportion of FOXP3+CD25+ 
cells in the tNGFR+ edited condition was found, possibly due to 
lower FOXP3 protein expression in edited cells. However, edited 
FOXP3+ Tregs isolated from the hu-mouse spleen were found to 
have similar suppressive capacity to WT counterparts. In addition, 
hu-mouse–derived FOXP3 edited Teff cells were found to be func-
tional in vitro and proliferate at comparable rates to WT Teff cells. 
These functional assays demonstrate that FOXP3 edited HSPCs 
retain the capacity to give rise to functional Tregs and Teff cells in vivo.
These results lay the foundation for using the FOXP3 CRISPR 
system to gene correct autologous HSPCs, T cell precursors, or Treg 
cells directly for clinical purposes. Ultimately, we envision the 
CRISPR system being used for FOXP3 gene repair in IPEX HSPCs 
for autologous transplantation, circumventing the need to find 
immunologically matched HSPC donors and lowering the risks 
associated with transplantation. More broadly, the translation of a 
CRISPR-based therapy for IPEX syndrome will help pave the way 
for similar therapeutic approaches in other primary immunodefi-
ciencies with autoimmunity.
MATERIALS AND METHODS
Cell isolation and culture
All research on cells from patients with IPEX and healthy donor 
controls was approved by the Stanford University Institutional 
Review Board (IRB) (in accordance with the IRB-approved proto-
col, IRB-34131) or by the IRB of the Ospedale San Raffaele (proto-
col TIGET06). Written informed consent was obtained from all 
patients or patient families. Additional healthy donor HSPCs were 
isolated from umbilical cord blood donors provided by the Binns 
Program for Cord Blood Research at the Stanford University or 
purchased commercially from AllCells or StemCell Technologies. 
For HSPC isolation from cord blood and bone marrow, mononu-
clear cells were first obtained by Ficoll-Paque (GE Healthcare) 
density gradient separation followed by ammonium chloride red 
blood cell lysis (STEMCELL Technologies). HSPCs were next puri-
fied by magnetic cell isolation using the CD34 MicroBead UltraPure 
Kit (Miltenyi Biotec) according to the manufacturer’s recommen-
dations and plated at a cell concentration of 2.5 × 105 cells/ml. The 
HSPCs were cultured at 37°C with 5% CO2 and low oxygen (5% O2) 
in StemSpan SFEM II medium (STEMCELL Technologies) supple-
mented with stem cell factor (100 ng/ml; PeproTech), IL-6 (100 ng/ml; 
PeproTech), thrombopoietin (100 ng/ml; PeproTech), Flt3L 
(100 ng/ml; PeproTech), 750 nM StemRegenin1 (STEMCELL Tech-
nologies), and 35 nM UM171 (STEMCELL Technologies). Additional 
healthy donor Treg and Teff cells were obtained from the Stanford Blood 
Center, and peripheral blood mononuclear cells were isolated by Ficoll- 
Paque density gradient separation. All edited cells were from male 
donor origin to match male IPEX patient samples, with the exception 
of a few female mock controls. Tregs and Teff cells were separated 
by magnetic bead isolation using the CD4+CD25+ Regulatory T Cell 
Isolation Kit (Miltenyi Biotec) according to the manufacturer’s pro-
tocol. Both cell fractions were activated with immobilized plate-bound 
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anti-CD3 [10 g/ml; OKT3 monoclonal antibody (mAb), Miltenyi] 
with soluble anti-CD28 mAb (1 g/ml; NA/LE, BD) for 2 to 3 days 
before editing and then switched to nonactivation conditions. Tregs 
were cultured in X-VIVO 15 (Lonza) with 5% human serum from 
male AB plasma (Sigma-Aldrich), IL-2 (300 U/ml; PeproTech), 
and 100 nmol rapamycin (STEMCELL Technologies; only added 
for certain experiments). Teff cells were cultured in X-VIVO 15, 
5% human serum, and IL-2 (50 U/ml). The Tregs and Teff cells were 
cultured at 37°C with 5% CO2 and ambient oxygen levels. Treg-like 
MT-2 cells were cultured in X-VIVO 15 with 5% human serum 
and 1% penicillin/streptomycin. K562 cells (American Type Culture 
Collection) were cultured in RPMI 1640 medium (Thermo Fisher Sci-
entific) with 10% fetal bovine serum (Thermo Fisher Scientific) 
at 37°C with 5% CO2 and ambient oxygen levels. For all cells, fresh 
medium was added every 2 to 3 days.
Screening of sgRNA efficiency by TIDE analysis
CRISPR chimeric sgRNA was designed using the Desktop Genetics 
web-based tool (Massachusetts Institute of Technology) and cloned into 
expression vectors using the px330 plasmid backbone (Addgene). The 
sgRNAs were placed under the human U6 promoter in the px330 
plasmid, which also contained an expression cassette for human 
codon–optimized SpCas9. For paired sgRNA nickase experiments, 
the sgRNAs were cloned into the px335 plasmid (Addgene) containing 
the Cas9 nickase expression cassette and were codelivered as paired 
plasmids. For the initial screen, 2 g of sgRNA/Cas9 plasmid DNA was 
nucleofected into 1 million K562 cells using the Lonza Nucleofector 
2b (program T-016). For each reaction, 100 l of nucleofection solution 
was used [100 mM KH2PO4, 15 mM NaHCO3, 12 mM MgCl2.6H2O, 
8 mM adenosine triphosphate, and 2 mM glucose (pH 7.4)]. The cells 
were cultured for 2 to 4 days, and genomic DNA was extracted 
using QuickExtract DNA Extraction Solution (Epicentre) according 
to the manufacturer’s recommendations. The site of DNA cleavage 
was PCR amplified using Herculase II Fusion Polymerase (Agilent 
Technologies) and primers flanking the region 5′-CTAGAGCTGG-
GGTGCAACTATGG-3′ and 5′-GACTACAATACGGCCTCCTCCTCTC-3′. 
The PCR amplicons were gel purified (Qiagen) and sequenced by 
Sanger sequencing using the forward primer 5′-CTAGAGCTGGG-
GTGCAACTATGG-3′. The resulting sequences were used to 
calculate indel frequencies using the TIDE analysis web-based 
software (https://tide.nki.nl/). A list of all sgRNA and primer se-
quences is provided in table S1.
FOXP3 homology donor design
The FOXP3 cDNA sequence was modified, or diverged, to incorpo-
rate synonymous mutations at the nucleotide level according to the 
redundant codon usage system to prevent premature recombina-
tion while still encoding for the WT FOXP3 protein. A constitutive 
Phosphoglycerate Kinase (PGK) promoter was positioned upstream 
of the tNGFR gene such that the marker would be expressed in all 
edited cells independent of FOXP3 expression. A strong Bovine 
Growth Hormone (BGH) pA signal was positioned after the FOXP3 
cDNA, and another pA was included after the tNGFR marker gene 
to allow independent expression of the FOXP3 cDNA and tNGFR 
and to ensure inactivation of the remaining endogenous FOXP3 
locus. The homology arms were centered on the cut site of the 
sgRNA 2. The 3′ arm (right arm) started at the cut site and reached 
approximately 650 base pairs (bp) downstream of the cut site, 
whereas the 5′ arm (left arm) included a region approximately 600 bp 
upstream of the cut site. The FOXP3FLcoW construct contained a 
shorter synthetic pA site in place of the BGH pA and shorter arms 
of homology to accommodate the addition of a WPRE element 
while maintaining an overall similar donor length.
Production of rAAV-FOXP3 homology donors
All FOXP3 homology donors were cloned into pAAV-MCS AAV 
vectors (Agilent Technologies) containing AAV inverted terminal 
repeats. Cloning was performed using Not I restriction digest [New 
England Biolabs (NEB)] followed by ligation with T4 DNA ligase 
(NEB). Plasmid preparation was performed by transforming plas-
mids into Stbl3 Escherichia coli (Life Technologies) and extracting 
plasmid DNA with Endotoxin-Free Maxi Prep kits (Qiagen). For 
rAAV production, pAAV-FOXP3 plasmids were cotransfected with 
rAAV6 helper plasmid DNA into the 293FT Cell Line (Life Tech-
nologies). After 72 hours, rAAV6-FOXP3 viral particles were extracted 
using the AAVpro kit (Clontech, Takara) according to the manu-
facturer’s instructions. The viral stocks were titered using quantitative 
PCR (qPCR) with primers and probe annealing to the inverted 
terminal repeats (ITRs). Briefly, the rAAV genomic DNA was iso-
lated using QIAamp MinElute Virus Spin Kit (Qiagen), qPCR 
was performed on the Roche LightCycler 480, and viral titer (vector 
genomes per microliter) was calculated using a standard curve 
generated from a circular pAAV-MCS-donor plasmid of known 
concentration.
Gene editing by nucleofection and rAAV transduction
Gene editing of primary human HSPCs, Tregs, and Teff cells was per-
formed using synthetic sgRNA 2 (5′-AGGACCCGATGCCCAAC-
CCC-3′) complexed to SpCas9 protein [Integrated DNA Technologies 
(IDT)] as an ribonucleoprotein (RNP) system. The sgRNA was synthe-
sized as a 100-mer RNA molecule with 2′-O-methyl 3′phosphorothio-
ate (MS) chemical modifications at the three terminal nucleotides 
on the 5′ and 3′ ends [5′-2'OMe(A(ps)G(ps)G(ps))ACC CGA UGC 
CCA ACC CCG UUU UAG AGC UAG AAA UAG CAA GUU 
AAA AUA AGG CUA GUC CGU UAU CAA CUU GAA AAA 
GUG GCA CCG AGU CGG UGC UUU 2'OMe(U(ps) U(ps)U)-3′; 
ps indicates phosphorothioate, and 2'OMe indicates 2′-O-methyl]. 
The sgRNAs were purified by reversed-phase high-performance 
liquid chromatography (HPLC) and quantified by mass spectrom-
etry. The sgRNAs were purchased from TriLink BioTechnologies 
and, in later experiments, from Synthego (not HPLC-purified), and 
editing rates triggered by sgRNAs from the two respective compa-
nies were comparable when tested in parallel. The sgRNA was com-
plexed with Cas9 for 10 min at 25°C at an approximate Cas9:sgRNA 
molar ratio of 1:2.5, using 8 g of sgRNA and 15 g of Cas9 per 
100 l of nucleofection solution containing 2.5 × 105 to 1 × 106 cells. 
After switching to high- fidelity (HiFi) Cas9 (IDT) that showed 
slightly lower efficiency in parallel experiments, the amount of 
HiFi Cas9 was increased, and the molar ratio was adjusted to 1:1.8, 
using 8 g of sgRNA with 22 g of HiFi Cas9 per 100 l of nucleofec-
tion solution. The sgRNA/Cas9 complexes were nucleofected into 
Tregs and Teff cells after 2 to 3 days of activation using the P3 Prima-
ry Cell Nucleofection Kit (Lonza) and the Lonza Nucleofector 4D 
(program E-0115). On the day of nucleofection, additional antibiotic 
(penicillin/streptomycin) was removed from the medium, and 
rapamycin was removed from the Treg medium. The following 
day, medium was changed, and antibiotic/rapamycin was re-
placed. For HSPC editing, the cells were nucleofected using the P3 
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Primary Cell Nucleofection Kit (Lonza) and the Lonza Nucleofector 
4D (program DZ-100). For analysis of indel frequencies, genomic 
DNA was extracted using QuickExtract DNA Extraction Solution 
(Epicentre), and TIDE analysis was performed as described above. 
For HDR experiments, rAAV6-FOXP3 donor transduction was 
performed following nucleofection at a multiplicity of infection 
(MOI) of 1 × 105 to 1 × 106 viral genomes per cell. After 24 hours 
of transduction, the medium was changed to remove excess viral 
particles.
Assessment of HDR-mediated targeted integration by flow 
cytometry and in-out PCR
To assess HDR at the genomic level, we performed in-out PCR 2 to 
4 days after editing using a forward primer outside of the 5′ arm of 
homology (5′-ATGTCAGCTCGGTCCTTCCA-3′) and a reverse 
primer inside the inserted divergent cDNA construct (5′-TGG-
CATAGGATTAAGGGAACTG-3′). A second in-out PCR strategy 
targeting the 3′ end used a forward primer inside the inserted 
tNGFR region (5′-AGCCTTCAAGAGGTGGAACA-3′) of the 
construct and a reverse primer in the endogenous FOXP3 locus 
outside of the 3′ arm of homology (5′-AGGCCATCCTGATCCT-
CAC-3′). As a control for the presence of genomic DNA, a PCR 
strategy targeting a downstream, unmodified region of FOXP3 was 
performed (forward primer: 5′-TGCCTCCTCTTCTTCCTTGA-3′; 
reverse primer: 5′-GAGCCTCGAAAACCCTGACT-3′). Herculase II 
fusion polymerase (Agilent Technologies) was used for all PCR 
amplification steps. The resulting PCR products were resolved by 
agarose gel electrophoresis. For absolute quantification of genomic 
integration events at the DNA level, an in-out PCR strategy quanti-
fied using the ddPCR (Bio-Rad) system was used. For ddPCR, we 
used two primer/probe sets: the first for the edited region of the 
FOXP3 locus (forward primer: 5′-GGGAGGATTGGGAAGACAAT-3′; 
FAM-labeled probe: 5′-TCAGAGATTGGAGGCTCTCC-3′; reverse 
primer: 5′-ACAATACGGCCTCCTCCTCT-3′) and a second primer/
probe control set targeting a nonmodified region of the FOXP3 
gene used as a reference (forward primer: 5′-CACCGAAATCGG-
TATTAGTTTG-3′; HEX-labeled probe: 5′-CAGTTCTGGAGGC-
CAGAGTC-3′; reverse: 5′-CCCGGGGGAGTATAGAAGG-3′). The 
two regions were amplified and quantified as previously described 
with modifications (19). The PCR used 100 ng of genomic DNA 
digested with Bam HI-HF (10 U) and an annealing temperature of 
62°C. The percentage targeting was calculated as the ratio of FAM 
(targeted allele) to HEX signal.
Enrichment of tNGFR+ edited cells
Edited tNFGR+ cells were enriched by fluorescence-activated cell 
sorting (FACS) 2 to 4 days after editing on a FACSAria II SORP (BD 
Biosciences). Cells were stained with anti-NGFR/CD271 mAb [Bio-
Legend, clone ME20.4, phycoerythrin (PE)–Cy7 conjugated or 
allophycocyanin (APC) conjugated]. When edited cells were present 
at low cell numbers, magnetic bead cell isolation was used to in-
crease yield and avoid cell loss associated with FACS. Positive 
selection of tNGFR+ cells was performed using CD271 (tNGFR) 
Microbead Kit (Miltenyi Biotec) according to the manufacturer’s 
instructions. Briefly, cells were magnetically labeled with anti-tNGFR 
microbeads and separated on an MS or LS column in the mag-
netic field of a MACS separator. Columns were washed and eluted, 
and the cells were passed through a second column to increase 
purity.
Off-target analysis
Off-target sites were bioinformatically predicted using the in silico 
COSMID prediction tool (25). For in vitro off-target analysis, 
GUIDE-seq was performed as previously described (26). In brief, 
the px330-FOXP3-sgRNA2-Cas9 plasmid was electroporated into 
U2OS cells along with a double-stranded oligodeoxynucleotide 
(dsODN; 5′-GTTTAATTGAGTTGTCATATGTTAATAACGGTAT-3′). 
The T7 and restriction fragment length polymorphism (RFLP) assays 
were performed to confirm editing and tag integration (using TIDE 
primers 5′-CTAGAGCTGGGGTGCAACTATGG and 5′-GACTA-
CAATACGGCCTCCTCCTCTC-3′). Genomic DNA was extracted, 
sequencing libraries were prepared, and NGS was performed to 
identify all sites in which the dsODN was integrated into DNA 
breaks. GUIDE-seq reads were filtered using a cutoff of eight mis-
matches according to previous studies on the CRISPR tolerance of 
mismatches (25, 40). A total of 62 sites identified by the combina-
tion of COSMID and GUIDE-seq analyses were then tested by NGS 
(Illumina MiSeq) in edited HSPCs. HSPCs derived from male 
healthy donor cord blood (n = 3) and bone marrow (n = 3) were edited 
with CRISPR sgRNA2/HiFi Cas9 combined with rAAV6-FOXP3 
FL donor, and total cells (tNGFR+/−) were used for genomic DNA 
extraction. NGS reads that were identified at similar rates in edited 
cells and mock-treated samples were eliminated from the analysis. 
High background in the mock-treated samples was attributed to the 
proximity of the sequencing primer to the polynucleotide sequence 
5′-CCCC-3′ in the sgRNA target site, as polyN sequences commonly 
cause errors in NGS and can lead to false-positive indel identifica-
tion. Only sites with indel mutation rates above mock control back-
ground were selected for NGS validation in edited bone marrow–
derived HSPCs. Four validated sites were identified in edited bone 
marrow–derived HSPC, and these sites were analyzed by bioinformatic 
gene annotation to predict expression in hematopoietic lineages 
and contribution to hematopoiesis or cell cycle regulation using the 
UCSC (University of California, Santa Cruz) genome browser, 
UniProt, GeneCards, and publically archived microarray and RNA 
sequencing data.
Determination of FOXP3 expression by RT-PCR and  
flow cytometry
FOXP3 mRNA expression was detected by RT-PCR in FOXP3FL 
edited CD4+ T cells and controls after 3 days of reactivation with 
Human T-Activator anti-CD3/28 Dynabeads (Life Technologies, 
1:25 bead:cell ratio). RNA was extracted with TRI Reagent (Sigma- 
Aldrich), and polyA+ mRNA was reverse transcribed into cDNA 
using SuperScript III First-Strand Synthesis System (Thermo Fisher 
Scientific). PCR amplification of FOXP3 cDNA was performed 
using Herculase II fusion polymerase (Agilent Technologies), and 
primers are listed in table S1. For assessing FOXP3 protein expres-
sion by flow cytometry, cells were fixed and permeabilized using 
FOXP3 staining solutions (eBioscience) and stained with anti- 
FOXP3 mAb (clone 259D/C7) conjugated to either AF647 (BD Bio-
sciences) or AF488 (BioLegend) following the manufacturer’s in-
structions. Fluorescence was detected on a FACSAria II SORP (BD 
Biosciences), analyzed using FlowJo software v4 10.5.0, and median 
florescence intensity (MFI) was recorded.
Treg phenotyping and suppression assay
For Treg phenotyping, cells were stained for flow cytometry using 
the following antibodies: CD25-BV605 (clone 2A3, BD Biosciences), 
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CTLA-4-PerCPCy5.5 (L3D10, BioLegend), FOXP3-AF647 (259D/
C7, BD), HELIOS-PE (22F6, BioLegend), NGFR-BV421 (cME20.4, 
BioLegend), PD1–fluorescein isothiocyanate (FITC) (MIH4, BD), 
and TIGIT-PE-Cy7 (MBSA43, eBioscience). Intracellular staining 
for FOXP3, CTLA-4, and HELIOS was performed after fixing and 
permeabilizing with FOXP3 staining solutions (eBioscience). Ex-
pression was detected on a FACSAria II SORP (BD Biosciences), 
and geometric mean intensity was analyzed using FlowJo software 
v4 10.5.0. The function of gene edited Tregs was tested by the sup-
pression assay using allogenic CD4+ T cell responders that were labeled 
with carboxyfluorescein diacetate succinimidyl ester (CFSE) prolifera-
tion dye (CellTrace CFSE Cell Proliferation Kit, Life Technologies). 
Responders were plated at a concentration of 2 × 104 cells per well and 
cocultured with Tregs at a 1:1 or 1:0.5 ratio of responders:suppressors. 
The cells were activated with a 1:25 ratio of beads:cells using Human 
T-Activator anti-CD3/28 Dynabeads (Life Technologies). As a refer-
ence control, responders were cocultured with an equal number of 
unstained Teff cells. The cells were cultured in 96-well round well 
plates and analyzed for CFSE staining on days 3 to 5 using a 
FACSAria II SORP (BD Biosciences). Nonactivated responders were 
used for gating, and the percentage of proliferated cells was analyzed 
using FlowJo software v4 10.5.0. Percent suppression was calculated 
using the following equation: % suppression = ((%proliferated R*) − 
(%proliferated R* + Treg))/((%proliferated R*) × 100), where R* 
represents stimulated CFSE-stained responder Teff. Treg purity 
was performed by flow cytometric analysis using the following 
antibodies: CD4-APC-Cy7 (RPA-T4, BioLegend), CD25-PE (4E3, 
Miltenyi), CD127-PerCP–Cy5.5 (A019D5, BioLegend), and FOXP3-
AF647 (clone 259D/C7, BD). The frequency of demethylated TSDR 
Tregs was quantified by epigenetic bisulfite qPCR in collaboration 
with Epimune/Epiontis GmbH (Berlin, Germany) as previously 
described (41).
Teff cytokine quantification and proliferation assay
Teff cytokine production was quantified using enzyme-linked im-
munosorbent assay (ELISA) for IL-2 (BD Biosciences), IFN- (BD 
Biosciences), and IL-17 (R&D Systems). Teff cells were activated using 
Human T-Activator anti-CD3/28 Dynabeads (Life Technologies) at 
a 1:25 ratio of beads:cells in 96-well round well plates at 2 × 105 cells per 
200 l. Supernatants were collected at 24 hours (IL-2) and 48 hours 
(IFN- and IL-17) after activation. For the proliferation assay, Teff 
cells were stained using the CellTrace CFSE Cell Proliferation Kit 
(Life Technologies) and cultured at 5 × 104 cells per well in 96-well 
round well plates. The stained cells were activated with a 1:25 ratio 
of anti-CD3/28 Dynabeads and analyzed for CFSE staining on days 
2 to 4 after activation on a FACSAria II SORP (BD Biosciences). 
The percentage of proliferated cells was determined using FlowJo 
software v4 10.5.0 and gated using nonactivated responders as a 
reference.
CFU assay to assess in vitro HSPC differentiation
Gene edited cord blood–derived HSPCs were FACS sorted 2 to 
4 days after editing and differentiated in vitro using the CFU assay. 
For each condition, 500 cells were plated in 1.1 ml of semisolid 
methylcellulose medium (MethoCult H4434, STEMCELL Technolo-
gies) and performed in duplicate or triplicate. The cells suspended 
in MethoCult were incubated at 37°C with 5% CO2 and ambient 
oxygen levels, and the resulting progenitor colonies were counted 
and scored after 14 days [BFU-E (primitive erythroid progenitors), 
CFU-E (mature erythroid progenitors), CFU-GM (granulocyte and 
macrophage progenitors), and CFU-GEMM (granulocyte, erythro-
cyte, macrophage, and megakaryocyte)].
Engraftment studies in immunodeficient mice
All animal experiments were conducted in accordance with the pro-
tocols approved by the Stanford University’s Administrative Panel 
on Laboratory Animal Care Research Committee under the Divi-
sion of Laboratory Medicine. Human cord blood–derived CD34+ 
HSPCs were gene edited as described above and injected 2 days 
after editing (without enriching for tNGFR+ cells). Cultured HSPCs 
were phenotyped by flow cytometry to ensure purity using the anti-
bodies CD34-PE-Cy7 (4H11, eBioscience), CD38-Percp-Cy5.5 
(HIT2, BioLegend), CD45RA-FITC (HI100, BD Biosciences), 
CD90-APC-Cy7 (5E10, BioLegend), CD49f-PE (GoH3, BioLegend), 
and combined lineage markers (Lin) on APC as follows: CD45-APC 
(30-F11, BioLegend), CD19-APC (HIB19, BioLegend), CD14-APC 
(HCD14, BioLegend), CD235a-APC (HIR2, BioLegend), CD20-
APC (2H7, BioLegend), CD16-APC (3G8, BioLegend), CD2-APC 
(RPA-2.10, BioLegend), CD3-APC (SK7, BioLegend), CD4-APC (SK3, 
BioLegend), CD8-APC (SK1, BioLegend), and CD13-APC (WM15, 
BioLegend). On the day of injection, 3- to 4-day-old NSG-SGM3 
(the Jackson laboratory, JAX:013062) neonatal pups were irradiated 
with 100 centigray and rested for 6 hours before injection. HSPCs 
(between 1.5 × 105 and 1.0 × 106) were resuspended in 30 l of 
expansion media, and cells were injected intrahepatically using a 
28.5-gauge insulin syringe. Starting at week 6, mice were checked 
for peripheral engraftment of human CD45+ cells via biweekly 
retro-orbital bleed. The mice were euthanized between 11 and 
14 weeks, and blood, spleen, bone marrow, and thymus were har-
vested. For blood and spleen samples, red blood cells were lysed 
following a 5-min incubation on ice with 1× red blood cell lysis buf-
fer (eBioscience) and were resuspended in staining buffer (phosphate- 
buffered saline, 0.25% bovine serum albumin, and 1 mM EDTA). 
Cells purified from tissues were stained using the following antibodies: 
hCD45 BV510 (HI30, BD Biosciences), mCD45-APC (30-F11, 
BioLegend), CD3-Percp-Cy5.5 (OKT3, BioLegend), CD56-PE (5.1H11, 
BioLegend), CD13-APC-Cy7 (WM15, BioLegend), and CD19-FITC 
(HIB19, BD Biosciences). An additional antibody panel for T cell 
subsets included hCD45 BV510 (HI30, BD Biosciences), mCD45 
PE (30-F11, BioLegend), CD4 APC-Cy7 (RPA-T4, BioLegend), 
CD8 BV650 (SK1, BioLegend), CD25 BV605 (2A3, BD Biosciences), 
CD45RA FITC (HI100, BD Biosciences), and FOXP3 AF647 
(259D, BioLegend). Cells were either analyzed by flow cytometric 
analysis (CytoFLEX BD) or sorted (BD, FACSAria). Sorted CD25high 
and CD25low populations were analyzed by suppression and prolifer-
ation assays, respectively, as described above.
Statistical analysis
Statistical analysis was performed using GraphPad Prism software 
v7.0c (GraphPad Inc.). Averages were represented as mean ± SD, 
and the number of replicates was indicated in respective figures and 
figure legends. For comparison of two datasets, two-tailed Student’s 
t test was performed ( = 5.0%). For paired donor samples, a paired 
Student’s t test was performed ( = 5.0%). Differences between multiple 
groups were identified using one- or two-way analysis of variance 
(ANOVA) and Tukey’s multiple comparisons test ( = 5.0%). Sig-
nificances were indicated as *P < 0.05, **P < 0.01, ***P < 0.001, and 
****P < 0.0001.
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SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/19/eaaz0571/DC1
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